Xtl生物製藥 XTLB 深 滬
已收盤 02-06 16:00:00 美东时间
1.07
+0.010
+0.94%
華盛通- 最 高1.08
- 今 開0.9804
- 成交量 3.84万股
- 最 低 0.9804
- 昨 收 1.06
- 總市值 1012.48万
- 52周最高 2.5699
- 市盈率 靜 --
- 換手率 0.41%
- 52周最低 0.5301
- 委 比 0.49%
- 總股本 946.24万
- 歷史最高 37.75
- 量 比 0.36
- 振 幅 9.40%
- 歷史最低 0.5301
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多XTL Update on Recent Developments
XTL Biopharmaceuticals Ltd. is working to finalize the acquisition of 85% of NeuroNOS Ltd. from Beyond Air Inc., following a binding letter of intent signed on January 13, 2026. The company plans to hold a shareholders' meeting on February 17, 2026, to approve a private placement of up to $2 million. The transaction and private placement aim to address the company's deficiency under Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5...
01-29 21:05
XTL announces receipt of Nasdaq notification
XTL Biopharmaceuticals (NASDAQ:XTLB) said on Friday it received a notice from Nasdaq on January 20, 2026, that the company is not in compliance with the continued listing requirements to maintain the ...
01-24 05:25
XTL Biopharmaceuticals Receives Nasdaq Noncompliance Notice, Gets Time Through March 6 To Regain Compliance
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC
01-24 05:11
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) received a notification from Nasdaq stating it doesn't meet the minimum $2.5 million stockholders' equity requirement for continued listing. The company reported a stockholders' equity deficit of $47,000 as of June 30, 2025, and doesn't meet alternatives for market value or net income. Nasdaq did not delist the company's ADSs immediately but gave XTL until March 6, 2026, to submit a compliance plan, with...
01-23 21:10
Why Is Beyond Air Stock (XAIR) Up Today?
Beyond Air stock gained after subsidiary NeuroNOS reached an agreement with XTL...
01-13 21:23
Beyond Air shares are trading higher after XTL Biopharmaceuticals agreed to acquire an 85% stake in its NeuroNOS subsidiary with Beyond Air set to receive up to $32.5 million in upfront, development and commercial milestone payments.
Beyond Air shares are trading higher after XTL Biopharmaceuticals agreed to acq...
01-13 20:34
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Biopharmaceuticals has entered a binding agreement to acquire 85% of NeuroNOS Ltd., a biotech company developing disease-modifying therapies for autism. The deal underscores the urgent need for effective autism treatments, with 1 in 31 U.S. children affected and no FDA-approved therapies targeting the core pathology. NeuroNOS, led by renowned autism researcher Prof. Haitham Amal and two Nobel Laureates in Chemistry, focuses on addressing nitr...
01-13 12:30
XTL Biopharmaceuticals receives Nasdaq bid price deficiency notice
XTL Biopharmaceuticals (XTLB) received a Nasdaq notice dated December 22, 2025, for failing to maintain the $1 minimum bid price requirement. The deficiency is based on the company’s ADS closing bid p...
2025-12-25 05:33
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
XTL Biopharmaceuticals Ltd. received a notice from Nasdaq indicating its ADSs are trading below the $1 minimum bid price requirement for the last 30 consecutive business days. The company has 180 days to regain compliance under Listing Rule 5810(c)(3)(A). If unable to meet the bid price requirement, XTL may request additional time by satisfying other listing standards, including a reverse stock split if needed. The company is evaluating options t...
2025-12-24 21:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 9.3% to $...
2025-12-24 05:05
